Dopamine D1 Antagonists for Restless Legs Augmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Restless Legs Syndrome (RLS) using dopamine receptor agonists often lead to augmentation, characterized by worsening symptoms and reduced efficacy over time, and alternative therapies like alpha-2-delta ligands and opioids come with side effects and dependency issues.
Innovation Solution
Administering a combination of dopamine D1 receptor antagonists with D3 receptor agonists, optionally with opioid agonists, to modulate receptor pathways and prevent or reverse augmentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dopamine receptor agonists are used to treat RLS, then initial symptom relief is achieved, but augmentation develops over time reducing efficacy
Solution Approach 1:
The patent applies inversion by switching from dopamine agonists (which initially work but cause augmentation) to dopamine antagonists (which block dopamine receptors). This reverse approach prevents the development of augmentation while maintaining symptom control, fundamentally changing the direction of pharmacological action to solve the long-term efficacy problem.
Solution Approach 2:
The patent changes the pharmacological parameter from agonist activation to antagonist blockade of dopamine receptors. By altering the fundamental mode of receptor interaction from stimulation to blockade, the treatment prevents augmentation while maintaining therapeutic effect, addressing the contradiction between initial efficacy and long-term durability.
2Reliability
If alpha-2-delta ligands are used as alternative therapy, then RLS symptoms are treated, but side effects such as dizziness and drowsiness occur
Solution Approach 1:
The patent extracts the therapeutic benefit of dopamine modulation while eliminating the harmful side effects by using selective dopamine antagonists. This approach isolates the desired symptom-relief mechanism from the adverse effects associated with other treatment classes like alpha-2-delta ligands.
Solution Approach 2:
The patent introduces dopamine antagonists as an intermediary mechanism that achieves symptom relief through a different pathway than alpha-2-delta ligands. By mediating treatment through dopamine receptor blockade rather than calcium channel modulation, the therapy maintains efficacy while avoiding the characteristic side effects of dizziness and drowsiness.
3Reliability
If opioids are used to treat RLS, then symptom relief is achieved, but risk of abuse and tolerance develops
Solution Approach 1:
The patent converts the potentially harmful opioid pathway into a beneficial non-opioid alternative by using dopamine antagonists. This approach achieves the same symptom relief benefit while eliminating the harmful elements of abuse potential and tolerance development, effectively using a different mechanism to achieve the same therapeutic goal without the associated risks.
Solution Approach 2:
The patent replaces long-term problematic opioid use with a safer, non-addictive dopamine antagonist approach. By using a medication that does not carry the same risks of abuse and tolerance, the treatment provides sustainable long-term symptom management without the accumulating harm associated with opioid therapy.
Data Source
AI summary
The present invention provides methods of treating Restless Legs Syndrome (RLS) including administering to a subject an effective amount of a dopamine D1 receptor antagonist. Compositions and kits useful for treating RLS are also provided.